CAS: 2719-21-3; N-(4-Acetylphenyl)Acetamide

上下游产品

N-acetyl-N-phenylacetamide acetic anhydride p-aminobenzophenone aniline (E)-N-(4-(3-(2-chlorophenyl)acryloyl)phenyl)acetamide 080539WR080539 acetic acid-[4-(4-methoxy-cinnamoyl)-anilide] trans-chalcone4-diethylamino-4'-acetylamino-trans-chalcone

📜(E)-4-Phenylazophenol置于zirconium(Iv) Oxide 碳酸氢钠,一水合肼,Zirconium(Iv) Oxide体系中,用 乙醇,水,1,2-二氯乙烷 用作溶剂,化学反应 19.0H,反应生成4-乙酰胺苯乙酮
参考文献:水合氧化锆上芳烃的区域特异性酰化和偶氮苯的选择性还原
标题:水合氧化锆上芳烃的区域特异性酰化和偶氮苯的选择性还原
摘要:已发现水合氧化锆是有效的和可重复使用的催化剂,用于芳烃的区域特异性酰化和选择性还原偶氮苯以分别生产苯并苯甲酮和苯.
Doi:10.1016/s0040-4039(97)00264-5

专利信息

专利号:US-2012165520-A1
优先权日:2010-12-23
标题:Process for the synthesis of prodrugs of opioids
发明人：MCGEE PAUL; GARNETT IAN; JUAN E; MANAGE A; CARNIAUX JEAN-FRANCOIS
权利人:MCGEE PAUL; GARNETT IAN; JUAN E; MANAGE A; CARNIAUX JEAN-FRANCOIS
摘要:The present invention provides a process for the synthesis of opioid prodrugs. In particular, the present invention provides a process for the synthesis of opioid prodrugs comprising: treating an opioid, in the form of a salt or a freebase, with a carbonyl synthon to form an activated intermediate and subsequently reacting the activated intermediate with an amine, in the form of a salt or a freebase.

专利号:US-11773118-B2
优先权日:2019-02-21
标 题:Methods of making high enantioselective secondary alcohols
发明人：YU CHENG-DER TONY; HSIEH YIH-HUANG; LIN SHU-YI; CHAO CHIN-SHENG; HSIEH YIN-CHENG; LAI MING-TAIN
权利人:OBI PHARMA INC
摘要:A new process to synthesis of compound OBI-3424 R-form and S-form products is provided. The “R-formâ€? compound OBI-3423 was first synthesized with 48% overall yield from compound OBI-3424-5 by installation of the labile phosphate motif at later stage. The stereo chemistry is established by 5 steps chemo-enzyme combination synthesis to afford 99% optical purity. After then, the “S-formâ€? compound OBI-3424 is prepared with improving overall yield of 54% from compound OBI-3424-5. The stereo chemistry is established by 4 steps combination of chemo-enzyme synthesis with excellent optical purity of 99%.

专利号:US-2022356182-A1
优先权日:2009-03-27
标题 :Inhibitors of hepatitis c virus replication
发明人：COBURN CRAIG A; LUDMERER STEVEN W; LIU KUN; WU HAO; SOLL RICHARD; ZHONG BIN; ZHU JIAN
权利人:MERCK SHARP & DOHME
摘要:The present invention relates to compounds of formula (I) that are useful as hepatitis C virus (HCV) NS5A inhibitors, the synthesis of such compounds, and the use of such compounds for inhibiting HCV NS5A activity, for treating or preventing HCV infections and for inhibiting HCV viral replication and/or viral production in a cell-based system.

专利号:US-11053243-B2
优先权日:2009-03-27
标 题:Inhibitors of hepatitis C virus replication
发明人：COBURN CRAIG A; LUDMERER STEVEN W; LIU KUN; WU HAO; SOIL RICHARD; ZHONG BIN; ZHU JIAN
权利人:MERCK SHARP & DOHME
摘要:The present invention relates to compounds of formula (I) that are useful as hepatitis C virus (HCV) NS5A inhibitors, the synthesis of such compounds, and the use of such compounds for inhibiting HCV NS5A activity, for treating or preventing HCV infections and for inhibiting HCV viral replication and/or viral production in a cell-based system.

专利号:US-9090661-B2
优先权日:2009-03-27
标 题:Inhibitors of hepatitis C virus replication
发明人：COBURN CRAIG A; MCCAULEY JOHN A; LUDMERER STEVEN W; LIU KUN; VACCA JOSEPH P; WU HAO; HU BIN; SOLL RICHARD; SUN FEI; WANG XINGHAI; YAN MAN; ZHANG CHENGREN; ZHENG MINGWEI; ZHONG BIN; ZHU JIAN
权利人:MERCK SHARP & DOHME
摘要:The present invention relates to compounds of formula (I) that are useful as hepatitis C virus (HCV) NS5A inhibitors, the synthesis of such compounds, and the use of such compounds for inhibiting HCV NS5A activity, for treating or preventing HCV infections and for inhibiting HCV viral replication and/or viral production in a cell-based system.

专利号:US-9090629-B2
优先权日:2010-11-03
标题:Cytotoxic agents comprising new ansamitocin derivatives
发明人：CHARI RAVI V J; WIDDISON WAYNE C; WILHELM SHARON D
权利人:CHARI RAVI V J; WIDDISON WAYNE C; WILHELM SHARON D; IMMUNOGEN INC
摘要:New ansamitocin derivatives bearing a linking group are disclosed. Also disclosed are methods for the synthesis of these new ansamitocin derivatives and methods for their linkage to cell-binding agents. The ansamitocin derivative-cell-binding agent conjugates are useful as therapeutic agents, which are delivered specifically to target cells and are cytotoxic. These conjugates display vastly improved therapeutic efficacy in animal tumor models compared to the previously described agents.